Chemed Corporation — 2010 Form 10-K
Reporting period: Fiscal year ended December 31, 2010. Although the request identifies 2010 Q4, this is an annual filing; the supplied text does not include standalone fourth-quarter operating results.
Business context
Chemed operated through two segments: Vitas, a hospice-care provider, and Roto-Rooter, which provides sewer, drain, pipe-cleaning, and plumbing services. Vitas’ revenue depends heavily on government reimbursement: more than 90% of its revenue came from Medicare and Medicaid payments. The filing incorporates the detailed financial statements and management discussion from the company’s 2010 Annual Report, but those figures are not included in the supplied text.
Financial metrics and capital
- Revenue, earnings, margins and cash flow: The provided filing text does not give clear consolidated values or year-over-year comparisons. Financial statements are incorporated by reference.
- Debt: At year-end, long-term debt had a carrying value of $159.2 million and an estimated market value of $189.1 million. Chemed had no variable-rate debt outstanding at December 31, 2010.
- Liquidity: Cash, current assets, current liabilities and available credit-facility capacity are not clearly stated in the supplied text.
- Vitas reimbursement: Medicaid represented 5% of Vitas revenue in 2010; physician services represented 2%. Medicare and Medicaid hospice base rates rose 1.8% on October 1, 2010.
- Medicare cap exposure: Chemed recorded a $62,000 liability for 2010 associated with one program and a $1.1 million fourth-quarter liability for three programs related to the first quarter of the 2011 cap-measurement year.
- Share repurchases and dividends: The company repurchased 1,501,772 shares in Q4 at a weighted average $64.09 per share. It paid $0.14 per share in Q4 dividends and $0.52 per share over 2010. The board authorized an additional $70 million under its repurchase program in December.
Material changes versus the prior comparable period
The supplied text does not provide comparable 2009 consolidated revenue, earnings, cash-flow, or margin figures, so the magnitude and drivers of annual operating changes cannot be assessed here. Chemed’s Q4 repurchases were substantially higher than in earlier quarters of 2010, and the quarterly dividend increased from $0.12 in Q1 and Q2 to $0.14 in Q3 and Q4.
Outlook, risks and unusual items
- No specific company earnings or revenue guidance is stated in the supplied text. Management notes that future dividends depend on earnings, financial condition, debt covenants and other factors.
- Vitas faces significant Medicare and Medicaid reimbursement, audit, eligibility, and payment-cap risks, along with potential changes in payment rates and regulations. Its Medicare billing practices remained under government investigation: the filing describes OIG and DOJ requests and subpoenas, plus Texas Attorney General document requests. The company said it could not predict the outcome and believed it was materially compliant.
- Other principal risks include nurse shortages and wage inflation, competition and referral-source dependence, healthcare regulation, litigation, and debt covenants and refinancing needs.
- Two employment-related class or collective actions were disclosed: a California Vitas wage-and-break case and a New York Roto-Rooter wage-and-overtime case. Chemed said it contested the allegations and could not estimate potential liability.
- Environmental liabilities related to the former DuBois business included a recorded $1.7 million accrual and contingent exposure up to $14.9 million. Management considered payment of the additional contingent amount not probable and recorded no provision for it.
- Management reported effective disclosure controls. The independent auditor’s report and complete financial statements are incorporated by reference, rather than reproduced in the supplied filing text.
Important facts for investors to verify
- Review the incorporated 2010 Annual Report for consolidated revenue, net income, segment results, margins, cash flows, balance-sheet liquidity and full debt maturities.
- Check Vitas’ Medicare/Medicaid reimbursement exposure, cap accruals, audit reserves and the status and potential consequences of the government investigations.
- Assess debt-covenant headroom, convertible-note dilution risk and the impact of the Q4 share repurchases on cash and leverage.
- Review subsequent developments in the employment litigation and DuBois environmental exposure.